Page 66 - Use Authorization News Today

Ellumes COVID-19 home-testing kit. Source: Ellume. Queensland medtech startup Ellume has secured a US$231.8 million ($304 million) contract with the US Department of Defense, to boost the production capabilities of its DIY COVID-19 testing kit. The contract, awarded in coordination with the US Department of Health and Human Services, will allow the business to expand its production capacity to 640,000 tests per day by December 2021. The US government plans to purchase 8.5 million of those tests...

INTRODUCTION We are continually bombarded with information about the COVID-19 pandemic and encouraged to receive the COVID-19 vaccines. Many are making the decision to consent or refuse these with little information. To make an informed decision about receiving a vaccine requires: 1) full and complete information regarding safety and side effects, 2) explanations of efficacy and effectiveness, 3) ingredients including any adjuvants, preservatives, and genetic material, and 4) vaccine companies�...

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Pfizer (NYSE:PFE) achieved several huge milestones in the fourth quarter of 2020. The big drugmaker, along with its German partner BioNTech, reported outstanding data from a l...

Emerging SARS-CoV-2 variants and the COVID-19 vaccination campaigns have increased complexity for COVID-19 testing. By Rachel West, Gigi Kwik Gronvall, and Amanda Kobokovich | February 2, 2021 A few months ago, concerns about COVID-19 diagnostic testing were mostly a matter of test availability and whether the results would be returned in soon enough to make a public health difference. Now, emerging SARS-CoV-2 variants and the COVID-19 vaccination campaigns have increased complexity for COVID-...

COVID-19 Response: Immunisation Annex - Appeal n° MDRCOVID19 Format Immunisation Funding Requirement: CHF 100 million New Funding requirements: CHF 1.9 billion IFRC-wide of which CHF 550 million is through the IFRC Emergency Appeal in support of National Societies. Appeal timeframe: 31 January 2020 - 31 December 2021 This Immunisation annex focuses on the pressing need of supporting COVID-19 vaccine roll-out globally. The IFRC considers the immunisation effort an obvious extension of its COVID...

The Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test from EKF Diagnostics is one of the first to detect both the presence and precise levels of COVID-19 neutralising antibodies. Click to read more...

Johnson & Johnson’s Janssen Pharmaceutical Companies announced on Friday its single-dose COVID-19 vaccine is 72% effective in the U.S. at preventing moderate to severe COVID-19.

J&J COVID-19 Vaccine Shows Complete Protection Against Hospitalization, 28 Days Post-vaccination NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said its single-shot Janssen COVID-19 vaccine candidate was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination. The vaccine candidate was 85 percent effective in preventing severe disease across all regions studied, 28 days after vaccination in all adults 18 years and older. The vaccine candidate showed complet...

1/29/2021 1:10:32 PM GMT | By Eren Sengezer Johnson & Johnson announced on Friday that its COVID-19 vaccine was 66% effective overall in the global trial, as reported by Reuters. The company further noted that the vaccine was 72% effective in the US portion of the trial. Market reaction This headline seems to be weighing heavily on market sentiment. As of writing, the S&P 500 Futures were down 1.2% on a daily basis. Meanwhile, Germanys DAX 30 was losing 1...

Though less effective than the two-dose versions, the vaccine from Johnson & Johnson given as a single shot is 72% effective in the U.S. at preventing moderate and severe Covid-19 cases, the company announced Friday. This September 2020 photo provided by Johnson & Johnson shows a clinician preparing to administer investigational Janssen Covid-19 vaccine. (Johnson & Johnson via AP) (CN) — Soon to be another weapon in the arsenal against the Covid-19 pandemic, pharmaceutical giant Johnson & Joh...